GlassScriptPhysician profile
Elizabeth Wirth
NPI 1245758416
$8,629.84
in general payments reported to CMS, 2019-2025
33 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,186 · 2022: $1,984 · 2023: $1,575 · 2024: $1,604 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,669 · Travel and Lodging: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,668.59 |
| Travel and Lodging | $791.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,938.34 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,295.94 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $539.05 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $474.72 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $424.75 | 2022-2025 | Watchman Access System, General - Therapies |
| Merck Sharp & Dohme LLC | $408.14 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $379.57 | 2023-2025 | |
| Preventric Diagnostics, INC. | $366.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $325.94 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $325.38 | 2023-2025 | |
| Amgen INC. | $300.32 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $281.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.32 | 2021-2022 | |
| Pfizer INC. | $222.74 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $193.54 | 2021-2024 | Onpattro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.88 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $118.84 | 2024-2025 | Optimizer |
| Kestra Medical Technology Services, INC. | $110.24 | 2023-2025 | Assure Wcd |
| Abiomed | $105.97 | 2023 | Impella |
| Daiichi Sankyo INC. | $58.80 | 2023 | Injectafer |
| Cvrx, INC. | $53.70 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $50.47 | 2023 | Arcalyst |
| Surmodics, INC. | $42.20 | 2023 | Pounce Thrombectomy, Pounce Venous Thrombectomy System, Sublime Radial Access Guide Sheath |
| Bridgebio Pharma, INC. | $34.03 | 2025 | Attruby |
| Lantheus Medical Imaging, INC. | $33.74 | 2024 | |
| Chiesi USA, INC. | $30.72 | 2021 | |
| Esperion Therapeutics, INC. | $27.40 | 2021-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $24.95 | 2022 | |
| Vifor Pharma, INC. | $24.67 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.11 | 2023 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $20.84 | 2021 | |
| Cmp Pharma, INC. | $18.60 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Wirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.